InvestorsHub Logo
Followers 9
Posts 1462
Boards Moderated 0
Alias Born 07/20/2012

Re: None

Monday, 05/25/2015 1:02:30 PM

Monday, May 25, 2015 1:02:30 PM

Post# of 700311
Quick question for the board. In one of the 2015 ASCO abstracts (e13055) the study includes results for GBM patients with pseudoprogression and indicates that 35% of the pseudo group had a median survival of 34.7 months. If there is a close correlation of PFS and OS typically seen in GBM, is this cause for concern in the DCVAX L trial? If the placebo group in the L trial ends up with a high percentage of psuedos, is it possible we may see a very high PFS threshold that the treatment group will have to exceed by 4 + months to reach the desired p value?
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News